EUVIMEDEUVIMED entdecken
Open Access

MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy

Julie Constanzo, Aliasghar Parach, Timothee David, Joshua Karam, Frank Bruchertseifer, Alfred Morgenstern, Marta Jarlier, Manuel Bardiès, Emmanuel Deshayes, Amelie Gudin-de-Vallerin, Florence Boissière-Michot, Evelyne Lopez-Crapez und 1 weitere

Journal of Nuclear Medicine · 2025-05 · 66 (5) · 785-792

DOI: 10.2967/jnumed.124.268857 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 27.02.2025. Verfasst von Julie Constanzo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Nuclear Medicine Department, Institut régional …. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Histocompatibility Antigens Class I. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preclinical and clinical studies increasingly show that the immune response plays a major role in radiotherapy. Here, we investigated the role of major histocompatibility complex class I (MHC-I) molecules recognized by cytotoxic CD8+ T cells in the response to radiopharmaceutical therapy (RPT).

Methods

Two murine melanoma cell lines that express low and high MHC-I levels (B16F10 and B16K1, respectively) were grafted in syngeneic or athymic and nude mice, and the response to a single injection of [225Ac]Ac-DOTA-TA99 monoclonal antibodies (9.25 or 18.5 kBq) was assessed and related to dosimetry. For clinical relevance, MHC-I expression was determined in samples from patients with well-differentiated, iodine-avid metastatic thyroid cancer and well-differentiated grade 2 mid-gut neuroendocrine tumors.

Results

RPT efficacy was enhanced by T-cell presence and MHC-I expression. In mice harboring B16F10 and B16K1 melanoma tumors, RPT showed a stronger antitumor effect in C57BL/6J (immunocompetent) animals than in athymic and nude (immunodeficient) animals, suggesting a crucial role of T-cell-mediated immune responses. Moreover, the response to irradiation was the same in B16K1 MHC-Ihigh tumors with a low absorbed dose of α-RPT and in B16F10 MHC-Ilow tumors with a 4 times higher absorbed dose. These results indicate that CD8+ T cells can counterbalance low tumor irradiation. Conversely, delivering high absorbed doses leads to side effects and seems to prevent immune system activation, thereby not taking advantage of these mechanisms. Our results also indicate that MHC-I can be used as a predictive biomarker of RPT response in lesions receiving low absorbed doses and that RPT treatment regimens should be reconsidered in the function of the MHC-I expression level.

Conclusion

This study shows that MHC-I expression can predict RPT immunostimulatory effects. This is relevant in metastatic disease where lesions in the same patient can receive very low or very high absorbed doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsHistocompatibility Antigens Class IAnimalsMiceHumansCell Line, TumorFemaleMice, NudeCD8-Positive T-LymphocytesAntibodies, MonoclonalMice, Inbred C57BLActinium

Stichwörter der Autor:innen

225AcT-cell adaptive immunitybystander immunitymicroenvironmentradioimmunotherapytargeted radionuclide therapy

Substanzen

RadiopharmaceuticalsHistocompatibility Antigens Class IAntibodies, MonoclonalActinium-225Actinium

Autor:innen und Institutionen

  • Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Nuclear Medicine Department, Institut régional du Cancer de Montpellier (ICM), Montpellier, France, and Équipe Labell…
  • Joint Research Centre, European Commission, Karlsruhe, Germany.
  • Biometrics Unit, Institut Régional du Cancer Montpellier, Montpellier, France; and.
  • Translational Research Unit, Institut Régional du Cancer Montpellier, Montpellier, France.

Zitieren

APA

Constanzo, J., Parach, A., David, T., Karam, J., Bruchertseifer, F., Morgenstern, A., Jarlier, M., Bardiès, M., Deshayes, E., Gudin-de-Vallerin, A., Boissière-Michot, F., Lopez-Crapez, E., & Pouget, J. P. (2025). MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 66(5), 785-792. https://doi.org/10.2967/jnumed.124.268857

Vancouver

Constanzo J, Parach A, David T, Karam J, Bruchertseifer F, Morgenstern A, et al. MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 2025;66(5):785-792. doi:10.2967/jnumed.124.268857

BibTeX
@article{Constanzo2025,
  author = {Constanzo, Julie and Parach, Aliasghar and David, Timothee and Karam, Joshua and Bruchertseifer, Frank and Morgenstern, Alfred and Jarlier, Marta and Bardiès, Manuel and Deshayes, Emmanuel and Gudin-de-Vallerin, Amelie and Boissière-Michot, Florence and Lopez-Crapez, Evelyne and Pouget, Jean-Pierre},
  title = {MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {5},
  pages = {785--792},
  doi = {10.2967/jnumed.124.268857}
}
Kostenlos starten →